It is currently Fri Oct 24, 2014 1:53 am

News News of Tysabri (Antegren or Natalizumab)

Site map of Tysabri (Antegren or Natalizumab) » Forum : Tysabri (Antegren or Natalizumab)

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Patient Registry for Tysabri

An FDA briefing document was released today that recommends a mandatory patient registry for Tysabri users. In August 2005 the FDA mandated an electronic registry for all patients & physicians using Accutane, and it was just announced last week that it is up and running. Hopefully a Tysabri registry won't take as long to implement.
Read more : Patient Registry for Tysabri | Views : 2286 | Replies : 6


Conflicts of interest

This one is from the BCP site.

"FDA PUTS FIVE SCIENTISTS WITH CONFLICTS OF INTEREST ON COMMITTEE EVALUATING CONTROVERSIAL MS DRUG:

Five of the eleven scientists so far selected to judge the safety of the new multiple sclerosis drug Tysabri have financial ties to either the drug's sponsors, Biogen and Elan Pharmaceuticals, or their competitors. The Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee will meet March 7 to reconsider Tysabri, ...
Read more : Conflicts of interest | Views : 1829 | Replies : 4


Testimony by Dr John Richert

A couple of weeks ago I posted part of an e-mail I had received from Dr John Richert, Vice Presdient of Research at the NMSS.

Attached is his testimony to the FDA about Tysabri.

Apologies if it has already been posted.

Ian

http://www.nationalmssociety.org/tysabr ... timony.asp
Read more : Testimony by Dr John Richert | Views : 2174 | Replies : 4


Wall Street Journal Editorial Today

Long URL but it should work for a week:


http://online.wsj.com/wsjgate?subURI=%2 ... TYwWj.html

Refers to Erbitux and Tysabri
Read more : Wall Street Journal Editorial Today | Views : 1414 | Replies : 1


Article from yesterday's Chgo Sun Times

This is the second article in the last two weeks that the Sun Times has run on Tysabri and this woman. Thought maybe someone would be interested. The tone of the article seems doubtful but she is very much an advocate.

http://nl.newsbank.com/nl-search/we/Arc ... p_docnum=1
Read more : Article from yesterday's Chgo Sun Times | Views : 2407 | Replies : 11


Monotherapy Question

Has anyone heard how much time needs to lapse between immunosuppressive treatments and Tysabri? I'm going to have one more Novantrone infusion next week.
Read more : Monotherapy Question | Views : 1417 | Replies : 1


Bring back Harry Z

Dear all,

Harry, I was just trying to wind you up. You know me well enough by now. I had no idea that your surname really began with Z.

Arron - sorry if this caused you any problems. I never ever though that the post would be taken seriously.

My latest survey shows that 97% want the ban on Harry Z to be lifted. Welcome back Harry Z.


Ian
Read more : Bring back Harry Z | Views : 1951 | Replies : 5


Ban Harry Z

This is not my idea, but I have received a huge number of PMs asking me to raise this with Arron.

My recent survey of users of this site showed that of the 654 who voted, 86% want Harry Z banned from the thisisms site.

Harry is a menace. I have received a number of e-mails saying that Harry Z holds a substantial amount of stock in Teva, which accounts for his unrelenting attacks on ...
Read more : Ban Harry Z | Views : 2070 | Replies : 5


testing for PML

Hi -

I've been reading through all the newly shared data and opinions on Tysabri and I have a question that maybe someone can answer. Does anyone know how the testing for PML is done? One description I read said they are taking "serial measurements of JC viral load" and I'm wondering just how those measurements are obtained.

Thanks,
Arcee
Read more : testing for PML | Views : 1197 | Replies : 0


TYSABRI® Two-Year Phase III Published in New England Journal

http://www.elan.com/news/print_full.asp?ID=824216

1 March 2006
TYSABRI® Two-Year Phase III Multiple Sclerosis Clinical Trial Results and Safety Evaluation Published in New England Journal of Medicine; TYSABRI Currently Under Review with U.S. and European Regulatory Authorities
CAMBRIDGE, Mass. and DUBLIN, Ireland, Mar 01, 2006 (BUSINESS WIRE) -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that two-year results from the two Phase III clinical trials evaluating TYSABRI(R) (natalizumab) ...
Read more : TYSABRI® Two-Year Phase III Published in New England Journal | Views : 2595 | Replies : 4


 

Login  •  Register


Statistics

Total posts 220833 • Total topics 22887 • Total members 14451


Contact us | Terms of Service